相关临床试验
3
1 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
2001
进行中（未招募）
1
33.3%
已完成
2
66.7%
暂无批准数据
- A comprehensive research report reveals 90 CD137-targeted therapies currently in clinical trials, representing a significant expansion in cancer immunotherapy development. - Major pharmaceutical companies including Roche, Genmab, and Sichuan Baili Pharmaceutical are actively advancing CD137-targeting therapies across multiple cancer indications. - Innovative technology platforms like AP Biosciences' T-cube enable creation of bispecific antibodies that selectively activate T-cells through CD137, potentially minimizing cytokine storm toxicities. - Combination therapy approaches combining CD137 agonists with checkpoint inhibitors and other targeted treatments show promise for overcoming monotherapy limitations.
- Ebenbuild received €2.3 million from the European Innovation Council Accelerator program to advance its AI-enabled digital twin platform for lung simulation and respiratory drug development. - The funding supports the market launch of Twinhale, the first scalable in silico trial software for pulmonary drug delivery that enables patient-specific predictions of drug deposition in lungs. - Validation studies demonstrate Twinhale's unprecedented accuracy in predicting local drug deposition, outperforming existing models and enabling design decisions typically inaccessible through traditional testing methods. - The company targets the rapidly growing €5 billion in silico trials market and aims to expand into clinical decision support systems and personalized medicine markets valued at over €300 billion by 2030.
- DelveInsight's 2025 pipeline report reveals over 20 companies actively developing more than 20 innovative therapies for HER2-positive gastric cancer treatment. - Merck's KEYNOTE-811 Phase III trial achieved its dual primary endpoint of overall survival in July 2024, evaluating Keytruda combination therapy for first-line treatment. - ENHERTU received US approval in April 2024 as the first tumor-agnostic HER2-targeted therapy for metastatic HER2-positive solid tumors. - Leading pipeline candidates include SHR-A1811 from Jiangsu HengRui Medicine, Cinrebafusp alfa from Pieris Pharmaceuticals, and BI-1607 from BioInvent International.
• Palvella Therapeutics is developing QTORIN 3.9% rapamycin anhydrous gel for rare genetic skin diseases, addressing unmet needs. • Phase 3 trial data for microcystic lymphatic malformations (mLMs) is expected in early 2026, with potential market launch in 2027. • H.C. Wainwright initiated coverage with a Buy rating and a $38 price target, projecting peak sales of $381 million by 2034. • Palvella's merger with Pieris Pharmaceuticals provides financial stability with $80 million in cash reserves, supporting operations into 2027.
